IP Library › Granted Patent US 11,167,028
Granted Patent B2
US 11,167,028 · App. 16/212,245 · Granted Nov 9, 2021

Cationic oil-in-water emulsions

Inventors: Luis Brito (Concord, MA); Michelle Chan (Florence, MA); Andrew Geall (Littleton, MA); Derek O'Hagan (Winchester, MA)
A61K39/39A61K9/1075A61K39/12A61K39/155A61K39/245A61K47/02A61K47/06A61K47/12A61K47/22A61K47/24A61K47/26A61K47/34C12N7/00A61K2039/5256A61K2039/53A61K2039/55555A61K2039/55566A61K2039/575C12N2710/16134C12N2710/16171C12N2710/16734C12N2710/16771C12N2760/18534C12N2760/18571C12N2770/36134C12N2770/36143C12N2840/203Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,167,028
App. No.
16/212,245
Granted
Nov 9, 2021
Kind
B2
Abstract

This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.

Claims (26)

1. A method for preparing a composition comprising an RNA molecule complexed with a particle of a cationic oil-in-water emulsion, comprising:

(i) providing an oil-in-water emulsion comprising particles that are dispersed in an aqueous continuous phase, wherein the average diameter of said particles is from about 80 nm to about 150 nm; wherein the average diameter does not change by more than 10% when the emulsion is stored at 4° C. for one month; wherein the emulsion comprises an oil and a cationic lipid, and wherein;

a. the ratio of oil:lipid (mole:mole) in the oil-in-water emulsion is at least about 8:1 (mole:mole),

b. the concentration of cationic lipid in said composition is at least about 1.25 mM, and

c. the cationic lipid is not DC-Cholesterol;

(ii) providing an aqueous solution comprising the RNA molecule; and

(iii) combining the oil-in-water emulsion of (i) and the aqueous solution of (ii), thereby preparing the composition.

2. The method of claim 1 , wherein the cationic oil-in-water emulsion of (i) and RNA solution of (ii) are combined at about 1:1 (v/v) ratio.

3. The method of claim 1 , wherein the aqueous solution comprising the RNA molecule comprises a salt.

4. The method of claim 3 , wherein the salt is NaCl.

5. The method of claim 4 , wherein the aqueous solution comprises about 20 mM NaCl.

6. The method of claim 1 , wherein the aqueous solution comprising the RNA molecule is a buffer.

7. The method of claim 6 , wherein the buffer is a citrate buffer.

8. The method of claim 7 , wherein the buffer comprises about 2 mM citrate.

9. The method of claim 1 , wherein the aqueous solution comprising the RNA molecule comprises a nonionic tonicifying agent.

10. The method of claim 9 , wherein the nonionic tonicifying agent is a sugar or sugar alcohol.

11. The method of claim 10 , wherein the nonionic tonicifying agent is selected from the group consisting of sucrose, trehalose, sorbitol, dextrose and combination thereof.

12. The method of claim 9 , wherein the nonionic tonicifying agent is sucrose.

13. The method of claim 12 , wherein the aqueous solution comprises about 560 mM sucrose.

14. The method of claim 1 , wherein the aqueous solution comprising the RNA molecule comprises a polymer.

15. The method of claim 1 , wherein the oil is squalene or squalane.

16. The method of claim 1 , wherein the particle further comprises a surfactant.

17. The method of claim 1 , wherein said cationic lipid is DOTAP.

18. The method of claim 1 , wherein the RNA molecule is a self-replicating RNA molecule that encodes an antigen.

19. The method of claim 18 , wherein the self-replicating RNA is an alphavirus-derived RNA replicon.

20. The method of claim 1 , wherein the average diameter of said particles is from about 80 nm to about 130 nm.

Continuity (6)
Continuation 15467660 · Mar 23, 2017
Division 14130886 · Apr 14, 2014
Provisional Application 61585641 · Jan 11, 2012
Provisional Application 61545936 · Oct 11, 2011
Provisional Application 61505109 · Jul 6, 2011
Related Publication 20190091329A1 · Mar 28, 2019